Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$13.44
0.0%
$10.77
$8.02
$18.80
$6.67B1.495.12 million shs3.13 million shs
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$108.80
-0.6%
$108.68
$95.49
$148.06
$6.71B0.38837,841 shs637,537 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.20
-0.1%
$10.59
$8.73
$13.06
$7.99B1.235.55 million shs5.92 million shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+0.52%+39.73%+24.35%-26.04%
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
-0.79%+2.28%-7.39%-19.79%+4.76%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-0.27%+5.56%-3.11%+5.75%+4.47%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.0718 of 5 stars
2.21.00.00.32.53.30.0
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
4.9056 of 5 stars
4.51.00.04.02.53.33.1
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.2931 of 5 stars
3.53.00.00.01.82.50.0
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.1712.89% Upside
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
2.92
Moderate Buy$184.0069.12% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.00
Buy$17.5056.25% Upside
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TRIL, ROIV, JAZZ, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
5/28/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$182.00 ➝ $172.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$167.00 ➝ $155.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$176.00 ➝ $147.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$183.00 ➝ $166.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
4/21/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
4/14/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.51$2.78 per share4.84$12.63 per share1.06
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.06B1.65$22.16 per share4.91$59.36 per share1.83
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M275.07N/AN/A$7.76 per share1.44
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7433.5915.102.504.60%6.78%3.03%8/14/2025 (Estimated)
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$414.83M$7.5015.325.821.0411.60%29.30%9.72%7/30/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$4.35B-$0.25N/AN/AN/A-119.54%-14.05%-12.81%8/6/2025 (Estimated)
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest TRIL, ROIV, JAZZ, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/6/2025Q1 2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
1.46
4.26
3.74
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
37.91
37.91
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.65 million491.54 millionOptionable
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
3,20061.65 million57.92 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860713.55 million657.18 millionOptionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

Recent News About These Companies

Trillium Therapeutics Stock Price History
Advances in Drug Discovery & Development 2024
Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$13.44 -0.01 (-0.04%)
Closing price 03:59 PM Eastern
Extended Trading
$13.42 -0.01 (-0.07%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$108.80 -0.65 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$108.61 -0.19 (-0.17%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.20 -0.01 (-0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$11.09 -0.11 (-0.99%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Trillium Therapeutics stock logo

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.